A Long-term Study of KT-621 Administered Orally to Participants With Asthma Previously Enrolled in a KT-621 Asthma Study
Condition(s) studied
Study summary
This Phase 2b open-label, long-term extension study is designed to evaluate the long-term safety and efficacy of KT-621 in participants with asthma who were previously enrolled in the parent study (KT621-AS-202) of KT-621 for asthma. The main goals of this study are to investigate the long-term safety and tolerability of KT-621, the long-term efficacy of KT-621 at treating asthma, and how KT-621 behaves in the body long-term.
Eligibility
Primary outcome measure(s)
- Incidence of treatment-emergent adverse events (TEAEs) — From baseline through Week 52
- Incidence of treatment-emergent serious adverse events (SAEs) — From baseline through Week 52
Trial sites (7)
| Facility | City | Region | Status |
|---|---|---|---|
| Kymera Investigative Site | Miami | Florida | Recruiting |
| Kymera Investigative Site | Tampa | Florida | Recruiting |
| Kymera Investigative Site | Dallas | Texas | Recruiting |
| Kymera Investigative Site | Berlin | Germany | Recruiting |
| Kymera Investigative Site | Poznan | Poland | Recruiting |
| Kymera Investigative Site | Kamenitz | Serbia | Recruiting |
| Kymera Investigative Site | Užice | Serbia | Recruiting |
More Kymera Therapeutics, Inc. trials in Poland
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07677059 on ClinicalTrials.gov ↗ ← All trials in Poland